Contact hours available until 10/31/2016.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Authors Conflict of Interest Disclosure:
The authors reported no actual or potential conflict of interest in relation to this continuing nursing education activity.

Nephrology Nursing Journal Editorial Board Statements of Disclosure:
In accordance with ANCC governing rules Nephrology Nursing Journal Editorial Board statements of disclosure are published with each CNE offering. The statements of disclosure for this offering are published below.

Paula Dutka MSN, RN, CNN, disclosed that she is a coordinator of Clinical Trials for the following sponsors: Amgen, Rockwell Medical, Keryx Biopharmaceuticals, Akebia Therapeutics, and Dynavax Technologies.

Carol M. Headley DNSc, ACNP-BC, RN, CNN, disclosed that she is a Consultant and/or member of the Corporate Speaker's Bureau for Sanofi Renal, and a member of the Advisory Board for Amgen.

Tamara M. Kear, PhD, RN, CNS, CNN, disclosed that she is a Fresenius employee, freelance editor for Lippincott Williams & Wilkins and Elsevier publishing companies, and a consultant for Symplmed.

All other members of the Editorial Board had no actual or potential conflict of interest in relation to this continuing nursing education activity.

This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Hazel A. Dennison, DNP, RN, APNc, CPHQ, CNE, ANNA Education Director.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
American Nephrology Nurses' Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910

Goal: To provide an overview of age-related differences in the use of an arteriovenous fistula (AVF) at the initial hemodialysis treatment.

Objectives

Explain how patients' ages may affect arteriovenous fistula (AVF) use at the initial hemodialysis treatment.
Discuss the importance of maintaining diligence in facilitating quality pre-ESRD care related to obtaining an AVF for use at the first hemodialysis treatment.

Rubette Harford MSN, RN

Appearances